Seamless eConsent, IRT, and eCOA Platform to Navigate Trial Complexity

From increased protocol procedures to longer trial duration times, clinical trials have steadily grown more complex over the years. Phase 2 and 3 protocol procedures have increased by 44% since 2009, while 78% of phase 2 studies have at least one substantial protocol amendment—making it even more difficult for researchers to keep track of changes and ensure accuracy throughout the trial duration.

The growing adoption of decentralized trials also adds another layer of complexity in maintaining supply— as shipping investigational medicinal products (IMPs) to multiple sites requires clear communication between storage systems and sources to secure timely refills and prevent study disruptions.

Sponsors, sites, and patients need systems that work together seamlessly, integrate easily with other tools, can be updated with precision, and are efficiently deployed. Given the additional demands placed on study teams today, personalized service from technology vendors is more important than ever.

Reducing risk in trials with seamless technology and quality services

Designing solutions to address these very real day-to-day trial challenges, while also helping study teams be well-positioned to keep pace with change, is crucial. This approach of practical innovation is the core design philosophy behind the Suvoda Platform.

The Suvoda Platform is a flexible eClinical ecosystem that delivers a seamless trial experience across eConsent, IRT, and eCOA to give sponsors and sites full command over mission-critical, time-sensitive patient interactions.

A key component of Suvoda’s purpose-built platform is an advanced IRT technology that has supported more than 1,000 trials across 80 countries to improve clinical and operational efficiency in randomization and drug supply.

Designed to deliver practical solutions for trial operations, Suvoda’s easy-to-use platform and exceptionally prepared client service teams excel with:

  • A flexible IRT to support mid-study changes: Suvoda IRT provides extensive features and configurability options to simplify the logistical challenges and complex protocols in decentralized, patient-centric trials for oncology, central nervous system, and rare diseases. Through its intuitive architecture, design, UI and reporting capabilities, study managers can easily make mid-study changes in real-time to meet the ever-changing demands of their trials—and hit tight deadlines.
  • Seamless interoperability for full data visibility: Suvoda’s single platform view across eConsent, IRT, and eCOA provides centralized trial data sharing and management. This increased data visibility enables study teams to more easily manage drug dosing and more accurately inform inventory supply management.
  • Always-on support with an assigned team that understands the protocol: A single team is assigned to every project for its entire lifecycle to support ease of use and mitigate anticipated issues before they arise. This proactive approach helps deliver a fast resolution of any unanticipated issues as well as an agile response to complex protocol changes later in the study.
  • Experience in the science and the technology: With expertise in oncology, central nervous system (CNS), and rare diseases, 75% of Suvoda’s clinical trials relate to complex therapeutic areas. That depth of experience—combined with the advantages of a fully customizable, modular architecture—gives your clinical trial the best chance of success.

Take command of your trials with Suvoda

Navigate the growing complexity of clinical trials with Suvoda’s practical, seamless eClinical platform and quality services—so you spend less time on the software and more time bringing novel therapies to patients who need them most.

Contact us at

About Clinical Trial Supply Forum 2024

Clinical supplies (CS) are mostly related to clinical trial supplies, including bulk materials and demand forecasts. During the past few decades, the supplies of drugs and medical devices have had some major challenges. The foundation of the clinical trial supply chain is uncertainty. It is challenging to run the supply chain effectively because variables like recruitment speed, patient attrition, maximum tolerated doses, titrations, and patient characteristics are intrinsically unknown. It's crucial to transmit accurate, current data throughout departments and consider the effects of actions made in one department on each other to produce an effective end-to-end clinical trial supply chain process. Yet, communication can be challenging because these decisions are frequently made by many teams with various goals in various systems.

Today more than ever, manufacturing resources are scarce and drugs are expensive. But did you know that 55-75% of drugs are wasted in an average trial? Not only does drug waste increase your costs; but it also leads to supply bottlenecks that slow down clinical programs. Unused supply delays the initiation of other trials that could have benefitted from having access to it and prevents you from bringing your drug to market on schedule. Stock-outs, which once more may be brought on by inadequately anticipated demand, may occur when there is a lack of consistency in supplies to keep patients taking the study drug.

This could occur as a result of an unexpectedly high initial enrollment rate, which strains the limited drug supply, as well as low production yields, which could delay the supply of comparative drugs. World BI organizing the CLINICAL TRIAL SUPPLY FORUM 2024 in which you can find industry experts and pharma professionals who continue to provide wide plate-form to tackle the most pressing challenges in the clinical trial sector.

Register with us to learn more!